patients with nonvalvular atrial fibrillation . In 2007, Bristol - Myers Squibb ( BMY ) and Pfizer ( PFE -0.3% ) entered into a global ..... commercialize apixaban, an oral anticoagulant discovered by BMY . Post your comment!
Aug 21 (Reuters) - Bristol - Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and...
Aug 21 (Reuters) - Bristol - Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.
Bristol - Myers Squibb (NYSE: BMY ) and Celgene (NASDAQ: CELG ) collaborate in a Phase 1 clinical ..... tolerability and preliminary efficacy of a combination regimen of Bristol - Myers ' Opdivo (nivolumab) and Celgene's Abraxane (paclitaxel
immuno-oncology, labeled "I-O" first by Bristol - Myers Squibb Co . (NYSE: BMY ), has emerged to become a new class of cancer ..... are occupied by Merck & Co. (NYSE: MRK ), Bristol - Myers , AstraZeneca PLC (NYSE: AZN ) and Roche Holding
believe a large portion of Bristol 's current valuation ..... clinical data are poor. Bristol carries a high price ..... upcoming patent losses. Bristol 's growth prospects ..... reinvestment in the business. Bristol - Myers Squibb discovers, develops
Allied Minds and Bristol - Myers Squibb ( BMY +0.1% ) form Allied- Bristol Life Sciences LLC to identify ..... clinical candidate is identified, Bristol - Myers will have the option to acquire
America, while the remainder comes from the United States and Europe. Mead Johnson operated as a subsidiary of Bristol - Myers Squibb from 1967 until it was spun off in 2009. We like Mead Johnson's infant nutrition-focused strategy, but it
Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's Avastin and Eli Lilly and Bristol - Myers Squibb 's Erbitux. If Kyprolis fails in head-to-head studies against leading proteasome inhibitor Velcade, Amgen
checkpoint inhibitor MPDL3280A in lung cancer patients. This follows similar deals with AstraZeneca, Merck, and Bristol - Myers Squibb , which are all focused on the potential for synergistic effects with other immuno-oncology products. We believe